FDx Advisors’s Coherus Oncology CHRS Stock Holding History

FDx Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,062	Closed	-$52K	–	651
2023 Q2	$52K	Sell	12,062 -161	-1%	-$950	﹤0.01%	741
2023 Q1	$97K	Hold	12,223	–	–	﹤0.01%	732
2022 Q4	$97K	Buy	12,223 +558	+5%	+$4.29K	﹤0.01%	732
2022 Q3	$112K	Sell	11,665 -1,947	-14%	-$19.7K	0.01%	711
2022 Q2	$99K	Buy	13,612 +1,738	+15%	+$15.1K	﹤0.01%	792
2022 Q1	$153K	Buy	+11,874	New	+$151K	0.01%	805
2021 Q4	–	Sell	-10,477	Closed	-$168K	–	849
2021 Q3	$168K	Buy	+10,477	New	+$154K	0.01%	798

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

FDx Advisors's CHRS Position: Q3 2023 in Review

FDx Advisors sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 12,062 shares — an estimated $52K sold.

FDx Advisors first reported a position in CHRS in Q3 2021 and held it in 7 quarters. The position peaked at $168K in Q3 2021. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

FDx Advisors reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
FDx Advisors sold 12,062 Coherus Oncology shares in Q3 2023, an estimated $52K.
FDx Advisors first reported a position in Coherus Oncology in Q3 2021 and held it in 7 quarters.
FDx Advisors's Coherus Oncology position peaked at $168K in Q3 2021.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on FDx Advisors's 13F filing for Q3 2023, filed 2 Nov 2023.